Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:Clipper Realty Inc. (CLPR) : This real estate company has seen the Zacks Consensus Estimate for its current year earnings increasing 43.6% over the last 60 days.REE Automotive Ltd. (REE) : This automotive technology company has seen the Zacks Consensus Estimate for its current year earnings increasing 46.3% over the last 60 days.Harmony Gold Mining Company Limited (HMY) : This gold-mining company has seen the Zacks Consensus Estimate fo ...

Atea Pharmaceuticals, Inc. (AVIR) has been on a downward spiral lately with significant selling pressure. After declining 8% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.Guide to Identifying Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whet ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Atea Pharmaceuticals, Inc. (AVIR) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Atea Pharmaceuticals, Inc. is a member of our Medical group, which includes 1017 different companies and currently sits at #5 in the Zacks Sector Rank. The Zacks ...

BOSTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that data highlighting the metabolic activation pathway of bemnifosbuvir were published in the peer-reviewed journal, PLOS Biology, in an article titled, “The activation cascade of the broad-spectrum antiviral bemnifosbuvir characterized at atomic resolution. ...

Atea Pharmaceuticals, Inc. (AVIR) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Sin ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Atea Pharmaceuticals, Inc. (AVIR) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.Atea Pharmaceuticals, Inc. is one of 1021 companies in the Medical group. The Medical group currently sits at #3 within the Zack ...

Second Quarter Financial and Business Update August 7, 2024 June 2020 NASDAQ: AVIR DISCLAIMERS Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our clinical results ...

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q2 2024 Results Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Jonae Barnes - Senior Vice President of Investor Relations and Corporate Communications Jean-Pierre Sommadossi - Founder, Chairman and Chief Executive Officer Arantxa Horga - Chief Medical Officer Janet Hammond - Chief Development Officer John Vavricka - Chief Commercial Officer Andrea Corcoran - Chief Financial Officer and Executive Vice President of Legal Conference Call Partici ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ | --- | --- | --- | |--------------------------------------------------------------------------------------------------------- ...

Exhibit 99.1 Atea Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update Full Enrollment Achieved in Global Phase 2 Hepatitis C Virus (HCV) Study; Complete SVR12 Results Expected 4Q'24 Bemnifosbuvir and Ruzasvir HCV Data Presented at EASL: Support Best-in-Class Potential with High Antiviral Potency, Low Risk of Drug Interaction, Short Treatment Duration and High Barrier to Resistance Results from COVID-19 Global Phase 3 SUNRISE-3 Trial Expected 2H'24 Conference Call at 4: ...